Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Recruiting
Observational Study
Relapsed Cancer
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- University Hospital, Bordeaux · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* age \> 18 years
* surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Exclusion Criteria:
* systemic therapy received for non-glioblastoma tumor
Contacts